All In Biotech

NDA 018264 · Ph Health

Dantrium

Dantrolene Sodium · Injection

Priority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Apr 2, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1979

Sep 19, 1979

Approved uses

3

Original approval plus efficacy supplements

Registered trials

12

4 Phase 3, 1 recruiting

FAERS reports

1,138

998 serious, 124 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 10, 2026.

INDICATIONS AND USAGE: Dantrium Intravenous is indicated, along with appropriate supportive measures, for the management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages. Dantrium Intravenous should be administered by continuous rapid intravenous push as soon as the malignant hyperthermia reaction is recognized (i.e., tachycardia, tachypnea, central venous desaturation, hypercarbia, metabolic acidosis, skeletal muscle rigidity, increased utilization of anesthesia circuit carbon dioxide absorber, cyanosis and mottling of the skin, and, in many cases, fever). Dantrium Intravenous is also indicated preoperatively, and sometimes postoperatively, to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 12, 1987 Supplement 11 · Efficacy
  • Feb 26, 1982 Supplement 3 · Efficacy
  • Sep 19, 1979 Original approval · Type 3 - New Dosage Form · priority review
1 products under this application
  • DANTRIUM · DANTROLENE SODIUM 20MG/VIAL · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Dantrolene" as an intervention, any sponsor and status, largest first.

All 12 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • neuroleptic malignant syndrome79
  • pyrexia63
  • pneumonia61
  • asthenia59
  • drug ineffective59
  • respiratory failure59
  • off label use54
  • urinary tract infection52
  • vomiting52
  • diarrhoea49
  • muscular weakness45
  • nausea45

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200445
200547
200654
200749
200859
200962
201061
201181
201283
201373
201443
201546
201663
201757
201845
201953
202042
202131
202236
202335
202427
202530
202616

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Dantrium (Dantrolene Sodium)

2024 spending

$8K

Beneficiaries

n/a

39 claims

Per beneficiary

n/a

$1.02 per unit

View as table
YearSpending
2020$29,516
2021$26,804
2022$17,162
2023$9,844
2024$7,941

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 91 on PubMed

Sponsor: Ph Health

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.